SCN9A and hereditary sensory and autonomic neuropathy: An important characteristic of the patients suffering from CIP is that even in the total absence of Nav1.7 activity, they do not exhibit any cognitive, cardiac, motor, or sensory deficits, supporting Nav1.7 as a valid—and indeed attractive—target for the development of drugs against pain.